Alphamab Oncology (9966.HK)

HKD 7.85

(21.52%)

Operating Expenses Summary of Alphamab Oncology

  • Alphamab Oncology's latest annual operating expenses in 2023 was 163.53 Million CNY , up 0.23% from previous year.
  • Alphamab Oncology's latest quarterly operating expenses in 2024 Q2 was 229.25 Million CNY , down 0.0% from previous quarter.
  • Alphamab Oncology reported a annual operating expenses of 468.02 Million CNY in annual operating expenses 2022, down -17.9% from previous year.
  • Alphamab Oncology reported a annual operating expenses of 570.03 Million CNY in annual operating expenses 2021, up 18.61% from previous year.
  • Alphamab Oncology reported a quarterly operating expenses of 173.92 Million CNY for 2023 Q2, down 0.0% from previous quarter.
  • Alphamab Oncology reported a quarterly operating expenses of 469.08 Million CNY for 2023 FY, up 0.23% from previous quarter.

Annual Operating Expenses Chart of Alphamab Oncology (2023 - 2017)

Historical Annual Operating Expenses of Alphamab Oncology (2023 - 2017)

Year Operating Expenses Operating Expenses Growth
2023 163.53 Million CNY 0.23%
2022 468.02 Million CNY -17.9%
2021 570.03 Million CNY 18.61%
2020 480.6 Million CNY 52.11%
2019 315.95 Million CNY 229.05%
2018 96.02 Million CNY 47.58%
2017 65.06 Million CNY 0.0%

Peer Operating Expenses Comparison of Alphamab Oncology

Name Operating Expenses Operating Expenses Difference
Uni-Bio Science Group Limited 325.05 Million HKD 49.689%
CK Life Sciences Int'l., (Holdings) Inc. 739.25 Million HKD 77.878%